CFM
INO icon

Catalyst Funds Management’s Inovio Pharmaceuticals INO Stock Holding History

Catalyst Funds Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,000
Closed -$34.6K – 576
2025
Q2 		$34.6K Buy
+17,000
New +$32.6K 0.01% 396
2024
Q2 		– Sell
-8,411
Closed -$117K – 1363
2024
Q1 		$117K Buy
+8,411
New +$72.6K 0.03% 368

Other funds holding INO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Catalyst Funds Management's INO Position: Q3 2025 in Review

Catalyst Funds Management sold out of Inovio Pharmaceuticals (INO) in Q3 2025, closing a stake of 17,000 shares — an estimated $34.6K sold.

Catalyst Funds Management first reported a position in INO in Q1 2024 and held it in 2 quarters. The position peaked at $117K in Q1 2024. 99 funds tracked by Wall St. Rank hold INO as of Q3 2025.

  • Catalyst Funds Management reported no remaining Inovio Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 17,000 Inovio Pharmaceuticals shares in Q3 2025, an estimated $34.6K.
  • Catalyst Funds Management first reported a position in Inovio Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Inovio Pharmaceuticals position peaked at $117K in Q1 2024.
  • 99 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2025.

Based on Catalyst Funds Management's 13F filing for Q3 2025, filed 12 Nov 2025.